We examined the role of metacognitive monitoring in strategic behavior during arithmetic problem solving, a process that is expected to shed light on age-related differences in strategy selection. Young and older adults accomplished better strategy-judgment, better strategy-selection, and strategy-execution tasks. Data showed that participants made better strategy judgments when problems were problems with homogeneous unit digits (i.e., problems with both unit digits smaller or larger than 5; 31×62) relative to problems with heterogeneous unit digits (i.e., problems with one unit digit smaller or larger than 5; 31×67) and when the better strategy was cued on rounding-up problems (e.g., 68×23) compared to rounding-down problems (e.g., 36×53). Results also indicated higher rates of better strategy judgment in young than in older adults. These aging effects differed across problem types. Older adults made more accurate judgments on rounding-up problems than on rounding-down problems when the cued strategy was rounding-up, while young adults did not show such problem-related differences. Moreover, strategy selection correlated with strategy judgment, and even more so in older adults than in young adults. To discuss the implications of these findings, we propose a theoretical framework of how strategy judgments occur in young and older adults and discuss how this framework enables to understand relationships between metacognitive monitoring and strategic behaviors when participants solve arithmetic problems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.actpsy.2017.09.005 | DOI Listing |
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.
Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.
Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Centre for Addiction and Mental Health, Toronto, ON, Canada.
Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.
Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!